157 related articles for article (PubMed ID: 20974239)
1. Antitumor efficacy of solid dispersion of paclitaxel prepared by supercritical antisolvent process in human mammary tumor xenografts.
Shanmugam S; Park JH; Chi SC; Yong CS; Choi HG; Woo JS
Int J Pharm; 2011 Jan; 403(1-2):130-5. PubMed ID: 20974239
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
[TBL] [Abstract][Full Text] [Related]
3. Toxicity studies of cremophor-free paclitaxel solid dispersion formulated by a supercritical antisolvent process.
Park JH; Chi SC; Lee WS; Lee WM; Koo YB; Yong CS; Choi HG; Woo JS
Arch Pharm Res; 2009 Jan; 32(1):139-48. PubMed ID: 19183887
[TBL] [Abstract][Full Text] [Related]
4. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
Desai N; Trieu V; Yao Z; Louie L; Ci S; Yang A; Tao C; De T; Beals B; Dykes D; Noker P; Yao R; Labao E; Hawkins M; Soon-Shiong P
Clin Cancer Res; 2006 Feb; 12(4):1317-24. PubMed ID: 16489089
[TBL] [Abstract][Full Text] [Related]
5. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
6. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
[TBL] [Abstract][Full Text] [Related]
7. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
9. Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy.
Sharma D; Chelvi TP; Kaur J; Chakravorty K; De TK; Maitra A; Ralhan R
Oncol Res; 1996; 8(7-8):281-6. PubMed ID: 8938791
[TBL] [Abstract][Full Text] [Related]
10. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
Auzenne E; Donato NJ; Li C; Leroux E; Price RE; Farquhar D; Klostergaard J
Clin Cancer Res; 2002 Feb; 8(2):573-81. PubMed ID: 11839679
[TBL] [Abstract][Full Text] [Related]
11. In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth.
Lee JY; Kim KS; Kang YM; Kim ES; Hwang SJ; Lee HB; Min BH; Kim JH; Kim MS
Int J Pharm; 2010 Jun; 392(1-2):51-6. PubMed ID: 20298770
[TBL] [Abstract][Full Text] [Related]
12. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route.
Chou TC; Dong H; Zhang X; Tong WP; Danishefsky SJ
Cancer Res; 2005 Oct; 65(20):9445-54. PubMed ID: 16230408
[TBL] [Abstract][Full Text] [Related]
14. Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes.
Niu R; Zhao P; Wang H; Yu M; Cao S; Zhang F; Chang J
J Drug Target; 2011 Jun; 19(5):373-81. PubMed ID: 20677917
[TBL] [Abstract][Full Text] [Related]
15. Physicochemical stability, pharmacokinetic, and biodistribution evaluation of paclitaxel solid dispersion prepared using supercritical antisolvent process.
Shanmugam S; Park JH; Chi SC; Yong CS; Choi HG; Woo JS
Drug Dev Ind Pharm; 2011 Jun; 37(6):628-37. PubMed ID: 21401339
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy.
Kim SC; Kim DW; Shim YH; Bang JS; Oh HS; Wan Kim S; Seo MH
J Control Release; 2001 May; 72(1-3):191-202. PubMed ID: 11389998
[TBL] [Abstract][Full Text] [Related]
17. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice.
Harper E; Dang W; Lapidus RG; Garver RI
Clin Cancer Res; 1999 Dec; 5(12):4242-8. PubMed ID: 10632366
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
Zhang C; Qu G; Sun Y; Wu X; Yao Z; Guo Q; Ding Q; Yuan S; Shen Z; Ping Q; Zhou H
Biomaterials; 2008 Mar; 29(9):1233-41. PubMed ID: 18093646
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo.
Zhu Z; Li Y; Li X; Li R; Jia Z; Liu B; Guo W; Wu W; Jiang X
J Control Release; 2010 Mar; 142(3):438-46. PubMed ID: 19896997
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]